NEW YORK (TheStreet) -- Biogen (BIIB) - Get Report stock closed up by 5.25% to $279.57 on Wednesday, due to expectations that Allergan (AGN) will pursue new acquisitions after its deal with Pfizer (PFE) was terminated

The biopharmaceutical company's stock climbed today due to speculation that the company could be acquired by Allergan, TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer wrote in an article today. 

However, acquiring Biogen may not be a "sensible" decision for Allergan, he said. 

"Allergan is interested in businesses that are growing at rates that are similar to, if not higher than, its own growth rate -- 10% annualized sales growth and 15% annualized earnings-per-share growth expected from 2016 to 2019," Cramer and Research Director Jack Mohr said in the article. "Biogen at best is expected to grow revenues and EPS at roughly 5% to 7% on an annualized basis over the same time period, which does not fit the Allergan bill."

Both Biogen and Allergan are holdings of Cramer's charitable trust.

Celgene stock also closed up 5.97% to $108.22 on Wednesday due to speculation that the company could be acquired by Allergan. 

(Biogen is held in Jim Cramer's charitable trust Action Alerts PLUS. See all of his holding with a free trial (link).)

Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Ratings rates this stock as a "buy" with a ratings score of B-. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and growth in earnings per share. We feel its strengths outweigh the fact that the company has had sub par growth in net income.

You can view the full analysis from the report here: BIIB

Image placeholder title